ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
14/111
1
ᏌᏁ
2
Most notably through the forthcoming global launch of VyeptiⓇ
and further indications in development for VyeptiⓇ and
RexultiⓇ/RxultiⓇ.
We have assessed and identified the most promising biological
clusters on which to focus our R&D efforts that enable us to
treat our targeted indication groups. These four biology clusters
are:
1. Hormonal / neuropeptide signaling: Targeting selected
pathways of pain signals and stress response;
4
2.
3
Figure 2: Lundbeck's R&D focus on four biological clusters
3.
4.
Circuit / neuronal biology: Targeting neurotransmission /
synaptic dysfunction to restore brain circuits and reduce
neurological, psychiatric, and pain symptoms;
Neuroinflammation /neuroimmunology: Targeting
neuronal loss due to an overactive immune system,
relevant across many niche and rare neurological
disorders;
Protein aggregation, folding, and clearance: Targeting
neurodegenerative proteinopathies involved in a range of
neurodegenerative diseases, e.g. Alzheimer's and
Parkinson's as well as rare diseases.
Our focus in niche and rare neurology and psychiatry provides
for a broad range of business development opportunities across
all stages of development. We will continue to pursue external
innovation through acquisitions, strategic partnerships and in-
licensing. Access to technologies and novel early-stage assets
will complement the four biological clusters and ensure we have
the best possible starting point for developing differentiated
medicines to patients with high unmet needs. Access to later-
stage products will seek to leverage our existing global
commercial infrastructure and provide for sustainable growth.
Rebuilding the pipeline
The R&D organization is transforming, adopting an agile
mindset to enable the team to be more flexible when necessary.
In this way, we will more effectively and efficiently rebuild our
pipeline with a balance of first-in-class and best-in-class drug
candidates, to enable a steady stream of breakthrough and
differentiated medicines across all phases of the pipeline.
We continue to orient R&D towards specialist treated disease
indications that address high unmet needs in niche and rare
disease neurology and psychiatry. We will use our four
biological clusters in our in-house discovery research to target
the high unmet needs within our expanded operating
space and to deliver impactful neuroscience medicines of the
future. Drawing on our experimental medicine expertise, we
now detect signals and gain more objective evidence to test
efficacy earlier in development - de-risking the path to the
market. We complement the rebuild of our pipeline with the right
blend of external innovation, mix of acquisitions, partnerships
and licenses for new medicines that fit with our refined focus on
niche neuroscience indications.
Maintain focus on profitability
Safeguarding a consistent level of profitability ensures our ability
to make strategic investments in our business. We increase cost
efficiency across the organization whenever we can by further
leveraging the knowledge and capabilities in our Group
Business Services center (GBS) in Poland.
We will continue to harness the power of technology and pull
digital capabilities into our ways of working to drive greater
efficiency. With our current product portfolio and projects in our
pipeline it is our ambition to reach an EBIT margin of more
than 25% by 2024.
Enhance organizational agility and collaboration
We work as global function teams, building on each other's
strengths and harnessing the full power of our functions and
departments across borders for greater outcomes. Working
cross-functionally and cross-geographically allows us full
clarity and alignment in terms of prioritization and decision
making and provides greater opportunity for our people through
the transfer of knowledge and talent development. We work in
alignment with our priorities and shared purpose, grounded in
our beliefs.View entire presentation